282 related articles for article (PubMed ID: 23363330)
1. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
[TBL] [Abstract][Full Text] [Related]
2. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
3. Healthcare costs and adherence associated with human regular U-500 versus high-dose U-100 insulin in patients with diabetes.
Eby EL; Zagar AJ; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
Endocr Pract; 2014 Jul; 20(7):663-70. PubMed ID: 24449672
[TBL] [Abstract][Full Text] [Related]
4. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
5. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
[TBL] [Abstract][Full Text] [Related]
6. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
7. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
8. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients.
Williams SA; Shi L; Brenneman SK; Johnson JC; Wegner JC; Fonseca V
J Diabetes Complications; 2012; 26(5):399-406. PubMed ID: 22699113
[TBL] [Abstract][Full Text] [Related]
9. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
[TBL] [Abstract][Full Text] [Related]
10. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
Eby EL; Boye KS; Lage MJ
J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
[TBL] [Abstract][Full Text] [Related]
11. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
12. Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy.
Han SH; Jing W; Mena E; Li M; Pinsky B; Tang H; Hebden T; Juday T
J Med Econ; 2012; 15(6):1159-66. PubMed ID: 22780707
[TBL] [Abstract][Full Text] [Related]
13. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics.
Bera R; Offord S; Zubek D; Lau G; Lin J; Baker RA; Karson C
J Med Econ; 2013; 16(4):522-8. PubMed ID: 23360177
[TBL] [Abstract][Full Text] [Related]
14. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.
Khemiri A; Kharitonova E; Zah V; Ruby J; Toumi M
Postgrad Med; 2014 Sep; 126(5):113-20. PubMed ID: 25295655
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
16. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of health care costs and utilization patterns for patients with gout.
Park H; Rascati KL; Prasla K; McBayne T
Clin Ther; 2012 Mar; 34(3):640-52. PubMed ID: 22381710
[TBL] [Abstract][Full Text] [Related]
18. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population.
Udall M; Louder A; Suehs BT; Cappelleri JC; Joshi AV; Patel NC
J Med Econ; 2013; 16(6):784-92. PubMed ID: 23565813
[TBL] [Abstract][Full Text] [Related]
19. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.
Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
J Med Econ; 2011; 14(4):497-507. PubMed ID: 21682606
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
Pawaskar M; Zagar A; Sugihara T; Shi L
J Med Econ; 2011; 14(1):16-27. PubMed ID: 21158486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]